US · Healthcare · Biotechnology
EPS came in at -0.03 against a street estimate of -0.05 — a beat of 40.0%.
Analysts rate Polaryx Therapeutics, Inc. Common Stock a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $7.50.
| Fund | Stake |
|---|---|
| Vanguard Capital Management, LLC | 3.33% |
| Geode Capital Management, LLC | 0.34% |
| Vanguard Fiduciary Trust Co | 0.21% |
| HRT FINANCIAL LLC | 0.16% |
| State Street Corp | 0.12% |
| BlackRock Inc | 0.08% |
| Jane Street Group LLC | 0.06% |
| Northern Trust Corp | 0.06% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Polaryx Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.